Sugi Predict

Sugi Predict / Compounds / Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

SCHEMBL670990

CC(O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)N)CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC1=O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR4SSTR5

The experimentally established mechanism targets of Somatostatin Receptor Ligand. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SSTR2 known ✓ P30874 17/20 0.60
▸ SSTR5 known ✓ P35346 14/20 0.60
▸ SSTR4 known ✓ P31391 12/20 0.60
▸ SSTR3 known ✓ P32745 11/20 0.60
▸ SSTR1 known ✓ P30872 7/20 0.60
▸ PLAU P00749 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29368491 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL29386529 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL8482 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL16062971 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL3046327 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin SCHEMBL29350200 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL12548326 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL31432768 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin SCHEMBL21361053 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1
Somatostatin Receptor Ligand SCHEMBL16186775 0.82 SSTR4 (0.83) SSTR2SSTR5SSTR4SSTR3SSTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189236-A1 COMPOSITION COMPRISING A (METH)ACRYLATE COPOLYMER, AN ALKALI OR AMMONIUM SALT OF A SATURATED ALIPHATIC MONOCARBOXYLIC ACID AND SPECIFIC GLIDANTS EVONIK OPERATIONS GMBH (DE) 2024-06-13 — — US disclosed
EP-4366710-A1 COMPOSITION COMPRISING A (METH)ACRYLATE COPOLYMER, AN ALKALI OR AMMONIUM SALT OF A SATURATED ALIPHATIC MONOCARBOXYLIC ACID AND SPECIFIC GLIDANTS Evonik Operations GmbH (DE) 2024-05-15 — — EP disclosed
EP-4366708-A1 HARD SHELL CAPSULES HAVING IMPROVED COLON RELEASE Evonik Operations GmbH (DE) 2024-05-15 — — EP disclosed
US-11980692-B2 Process for preparing a coated hard shell capsule EVONIK OPERATIONS GMBH (DE) 2024-05-14 — — US disclosed
EP-4346780-A1 HARD-SHELL CAPSULE WITH INFLUX PREVENTION OF GASTRIC FLUIDS Evonik Operations GmbH (DE) 2024-04-10 — — EP disclosed
EP-4346779-A1 HARD SHELL CAPSULES WITH MODIFIED RELEASE COATING Evonik Operations GmbH (DE) 2024-04-10 — — EP disclosed
CN-117377466-A Hard shell capsule for preventing gastric juice from flowing in 赢创运营有限公司 2024-01-09 — — CN disclosed
CN-117355295-A Hard shell capsule with modified release coating 赢创运营有限公司 2024-01-05 — — CN disclosed
WO-2023214016-A1 DOSAGE FORM WITH DRUG RELEASE AT PH 3 TO 6 USING DOUBLE COATING SYSTEM WITH AT LEAST ONE RELEASE ACCELERATION AGENT EVONIK OPERATIONS GMBH (DE) 2023-11-09 — — WO disclosed
WO-2023174722-A1 PRE-FUNCTIONALIZED HARD SHELL CAPSULE WITH ACCELERATED DRUG RELEASE AT PH VALUE 5 TO 5.5 EVONIK OPERATIONS GMBH (DE) 2023-09-21 — — WO disclosed
US-20140079792-A1 COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS EVONIK ROEHM GMBH (DE) 2014-03-20 — — US disclosed
WO-2014032742-A1 PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH SUSTAINED RELEASE CHARACTERISTIC AND WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EVONIK INDUSTRIES AG (DE) 2014-03-06 — — WO disclosed
WO-2014032741-A1 GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EVONIK INDUSTRIES AG (DE) 2014-03-06 — — WO disclosed
EP-2605759-A1 GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL FORMULATION COMPRISING ONE OR MORE SALTS OF ALGINIC ACID Evonik Röhm GmbH (DE) 2013-06-26 — — EP disclosed
CN-103068376-A Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid EVONIK ROEHM GMBH 2013-04-24 — — CN disclosed
WO-2012171884-A1 GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EVONIK RÖHM GMBH (DE) 2012-12-20 — — WO disclosed
WO-2012171575-A1 COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS EVONIK RÖHM GMBH (DE) 2012-12-20 — — WO disclosed
WO-2012171576-A1 COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS EVONIK RÖHM GMBH (DE) 2012-12-20 — — WO disclosed
US-20120093926-A1 GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL FORMULATION COMPRISING ONE OR MORE SALTS OF ALGINIC ACID EVONIK ROEHM GMBH (DE) 2012-04-19 — — US disclosed
WO-2012022498-A1 GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL FORMULATION COMPRISING ONE OR MORE SALTS OF ALGINIC ACID EVONIK RÖHM GMBH (DE) 2012-02-23 — — WO disclosed